Navigation Links
Combination of drugs produces dramatic tumor responses in advanced melanoma patients
Date:6/2/2013

CHICAGO, JUNE 2, 2013 The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Several patients experienced tumor shrinkage of more than 80 percent within 12 weeks of receiving the drugs, and the shrinkage was long lasting. Further, 40 percent of patients who received varying concurrent dosages had an objective response meaning at least a 50 percent reduction in tumor size. Side effects from the drug combination were manageable and often reversible.

"We are very excited about the response rates these patients have experienced. This kind of deep and rapid tumor regression has never been seen in melanoma using immunotherapy, and suggests that these two drugs could be better used in combination than alone," said Jedd D. Wolchok, MD, PhD. Dr. Wolchok, a medical oncologist at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering, is lead author on The New England Journal of Medicine paper and also presented the findings at ASCO.

Dr. Wolchok and his team combined ipilimumab and nivolumab because promising results in preclinical testing suggested the drugs impact the immune system in a complementary way. By blocking the inhibitory marker CTLA-4, ipilimumab, which the FDA approved for advanced melanoma in 2011, activates the immune system, prompting T cells to start attacking the tumor. Blocking PD-1 further activates T cells in a different manner, allowing them to continue the attack.

"Previous studies had shown that ipilimumab alone could prolong overall survival in advanced melanoma patients, and nivolumab alone could produce durable tumor responses in melanoma and other cancers, so the combination of the two drugs was quite logical and well supported by preclinical and clinical trial data," he said.

However, Dr. Wolchok notes that not all patients respond to immunotherapy and determining why some patients do not is becoming an extremely important part of advancing this field.

Because of the strong Phase I findings, researchers will begin testing the combination this June as a therapy for patients newly diagnosed with advanced melanoma in a randomized Phase III trial led by Memorial Sloan-Kettering and taking place at more than 150 institutions worldwide.


'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
646-227-3956
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Melanoma Patients Receive Promising News Regarding Cancer Immunotherapy Combination Treatment
2. Underactive Thyroid and Heart Failure a Bad Combination: Study
3. Learn How to Incorporate Ayruveda into Yoga Practices, Discover Dosha Combinations, and How to Live in Balance this Saturday, May 18th at The YogaSoul Center
4. Added benefit of saxagliptin/metformin combination is not proven
5. New drug combination therapy developed to treat leukemia
6. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
7. Different drug combinations work best for prevention versus treatment of colorectal tumors
8. Combination therapy provides similar clinical benefit as single drug treatment in MS
9. Comparing combination therapies for advanced head and neck cancer shows no improvement
10. New drug combination could prevent head and neck cancer in high-risk patients
11. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
Breaking Medicine Technology: